Jason Tache, DO
Hematology & Oncology · Plantation, FLNPI 1679561294
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (44.0%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 53 manufacturers reported payments, led by Bristol Myers Squibb at 44.6% of the total. Reporting peaked in 2019 at $10,094 and has fallen 91.0% since, to $913 in 2025.
Across 515 payments — averaging $36.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$8K
- Novartis$2K
- Johnson & Johnson$1K
- E.r. Squibb & Sons, L.L.C.$1K
- Pfizer$695
- Incyte Corporation$578
- plus $5K from 47 others
Across 226 payments — averaging $5170.61 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$484K
- Novocure Inc.$283K
- Incyte Corporation$79K
- Bristol Myers Squibb$72K
- Astrazeneca UK Limited$62K
- Eli Lilly$58K
- plus $131K from 10 others
What the payments were for
- Consulting fees$6,70035%
- Travel & lodging$1,3787%
- Food & beverage$8,34344%
- Education$1,2266%
- Other$1,2987%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,944 in reported general payments places this provider in the 70th percentile of 694 hematology & oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 50 | $747,454 |
| JakafiRuxolitinib Phosphate | 46 | $736,984 |
| RevlimidLenalidomide | 35 | $707,292 |
| PromactaEltrombopag Olamine | 22 | $599,963 |
| QinlockRipretinib | 11 | $457,348 |
| XtandiEnzalutamide | 35 | $401,189 |
| ImbruvicaIbrutinib | 29 | $317,529 |
| TabrectaCapmatinib Hydrochloride | 13 | $276,963 |
| InlytaAxitinib | 13 | $274,893 |
| OpdivoNivolumab | 18 | $263,980 |
| AvastinBevacizumab | 33 | $206,854 |
| EliquisApixaban | 272 | $198,222 |
| VenclextaVenetoclax | 21 | $166,615 |
| LynparzaOlaparib | 18 | $146,972 |
| Sandostatin Lar DepotOctreotide Acetate,mi-Spheres | 14 | $95,694 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisPromacta, Tabrecta, Sandostatin Lar Depot, Tasigna | $2,194 | $1,057,67564 claims |
| Incyte CorporationJakafi | $578 | $736,98446 claims |
| Bristol Myers SquibbRevlimid | $8,454 | $707,29235 claims |
| PfizerInlyta, Eliquis, Nivestym | $695 | $490,439297 claims |
| Astellas Pharma US IncXtandi | $289 | $401,18935 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $23 | $317,52929 claims |
| E.r. Squibb & Sons, L.L.C.Opdivo | $1,095 | $263,98018 claims |
| AbbVieVenclexta, Creon | $368 | $194,65537 claims |
| AstraZenecaLynparza | $367 | $146,97218 claims |
| AmgenXgeva | $99 | $86,55326 claims |
| Johnson & JohnsonXarelto | $1,231 | $44,09457 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $16 | $54273 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 694 hematology & oncology providers in Florida.
Other hematology & oncology in Plantation
- Harshad AminPlantation$159K
- Martin DietrichRockledge$6.2M
- Mark SocinskiOrlando$2.4M
- Tarek MekhailOrlando$2.2M
- Edgardo SantosFort Lauderdale$2M
- Daniel LandauOrlando$1.8M
- Wassim McHaylehAltamonte Springs$1.5M
- Edith PerezJacksonville$1.1M
- Steven FeinMiami$1M
- Vamsidhar VelchetiJacksonville$966K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.